GCP
NPCE icon

GSA Capital Partners’s Neuropace NPCE Stock Holding History

GSA Capital Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Buy
117,672
+87,751
+293% +$1.32M 0.1% 264
2025
Q4 		$462K Sell
29,921
-24,615
-45% -$329K 0.04% 874
2025
Q3 		$562K Buy
54,536
+1,323
+2% +$12.5K 0.05% 768
2025
Q2 		$593K Sell
53,213
-1,855
-3% -$23.2K 0.04% 806
2025
Q1 		$677K Sell
55,068
-1,316
-2% -$16.5K 0.06% 588
2024
Q4 		$631K Buy
+56,384
New +$490K 0.05% 728

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GSA Capital Partners's NPCE Position: Q1 2026 in Review

GSA Capital Partners increased its Neuropace (NPCE) stake by 293% in Q1 2026, buying an estimated $1.32M and bringing the position to 117,672 shares worth $1.55M. The position accounts for 0.1% of the portfolio, ranked #264.

GSA Capital Partners first reported a position in NPCE in Q4 2024 and has held it in 6 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • GSA Capital Partners held 117,672 shares of Neuropace worth $1.55M as of Q1 2026.
  • GSA Capital Partners bought 87,751 Neuropace shares in Q1 2026, an estimated $1.32M.
  • Neuropace made up 0.1% of GSA Capital Partners's portfolio in Q1 2026, its #264 holding.
  • GSA Capital Partners first reported a position in Neuropace in Q4 2024 and has held it in 6 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.